Which generation of targeted drug is Osimertinib?

Osimertinib is a third-generation targeted drug. Osimertinib is suitable for patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon19 deletion or exon21 Adjuvant therapy after tumor resection in adult patients with an L858R mutation (as detected by a U.S. Food and Drug Administration-approved test) and patients with metastatic non-small cell lung cancer whose tumors have an EGFRexon19 deletion or exon21 First-line treatment of adult patients with the L858R mutation as detected by a U.S. Food and Drug Administration-approved test. Osimertinib is also indicated for the treatment of metastatic EGFR as detected by a U.S. Food and Drug Administration (FDA)-approved test Adult patients with T790M mutation-positive non-small cell lung cancer whose disease has progressed during or after EGFR·TKI treatment.

Osimertinib(Osimertinib) is a type of kinase inhibitor called , which prevents cancer cells from multiplying by blocking the action of abnormal proteins. Common (greater than 10%) adverse reactions of osimertinib include diarrhea, stomatitis, rash, dry and itchy skin, paronychia, thrombocytopenia, and decrease in white blood cells and neutrophils. Occasional adverse reactions to osimertinib (1%-10%) include interstitial lung disease. Osimertinib is metabolically inactivated in the liver through CYP3A4 and CYP3A5. Hepatic enzyme inhibitors such as macrolide antibiotics, antifungals and antiviral drugs can prolong the action time of osimertinib, while hepatic enzyme inducers such as rifampicin will reduce the efficacy of osimertinib. Generic drugs cost several hundred yuan per box. Different versions have different prices. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0